World-first pediatric telesurgery using SSi Mantra at SS Innovations (SSII)

Rhea-AI Filing Summary

SS Innovations International, Inc. reported that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system. This means a complex kidney-related procedure in a child was carried out remotely with the help of the company’s robot-assisted platform, highlighting a significant technical and clinical milestone for its technology. The company furnished a press release with additional details as an exhibit to this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001676163 0001676163 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 16, 2025

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Florida		001-42615		47-3478854
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

405, 3rd Floor, iLabs Info Technology Centre Udyog Vihar, Phase III Gurugram, Haryana India		122016
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: +91 73375 53469

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
Common Stock		SSII		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.

Item 8.01 Other Events.

On September 16, 2025, the Company issued a press release announcing that the world’s first pediatric pyeloplasty telesurgery had been successfully performed by utilizing the Company’s SSi Mantra surgical robotic system.

A copy of the press release is included as Exhibit 99.1 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated September 16, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2025	SS INNOVATIONS INTERNATIONAL, INC.
	By:	/s/ Sudhir Srivastava
		Sudhir Srivastava, M.D.
		Chairman and Chief Executive Officer

2

FAQ

What did SSII disclose in this Form 8-K filing?

The company disclosed that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system and furnished a related press release as an exhibit.

What medical procedure was involved in SSII’s announcement?

The announcement involved a pediatric pyeloplasty telesurgery, a surgery addressing a blockage or narrowing where the kidney meets the ureter, performed remotely using the SSi Mantra robotic system.

Which SS Innovations product was used in the pediatric telesurgery?

The procedure used SS Innovations’ SSi Mantra surgical robotic system, which enabled the pediatric pyeloplasty to be performed as a telesurgery.

Does the SSII 8-K include financial results or earnings data?

No financial results or earnings data are described; the filing focuses on the successful pediatric pyeloplasty telesurgery conducted with the SSi Mantra robotic system.

What exhibit is attached to the SSII 8-K related to this event?

Exhibit 99.1 is a press release dated September 16, 2025, which provides additional information about the pediatric pyeloplasty telesurgery performed using the SSi Mantra system.

Who signed the SSII 8-K report?

The report was signed on behalf of SS Innovations International, Inc. by Sudhir Srivastava, M.D., the company’s Chairman and Chief Executive Officer.